Silence Therapeutics Plc American Depository Share (SLN) Stock
Key stats
- Market cap
- $1.23B
- Price / Earnings ratio
- -15.6x
- EPS (TTM)
- -$1.32
- Volume
- Loading
- 52-week high
- $19.87
- 52-week low
- $4.19
Source: third-party data provider, as of November 13, 2026
Compare with SLN
Recent news

Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
SLN

Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
SLN

Silence Therapeutics jumps 59% on Merck takeover
Silence Therapeutics jumps 59% on Merck takeover
SLN

SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
SLN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 77.98
- MACD 12/26/9
- 1.80
- EMA 9 of MACD
- 1.95
- MACD histogram
- -0.15
- SMA 50
- $14.46
- Price above SMA 50
- EMA 50
- $15.54
- Price above EMA 50
- SMA 200
- $9.63
- Price above SMA 200
- EMA 200
- $10.45
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
SLN

Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
SLN

Silence Therapeutics jumps 59% on Merck takeover
Silence Therapeutics jumps 59% on Merck takeover
SLN

SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
SLN

Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
SLN

Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
SLN

Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SLN

Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
SLN

Silence Therapeutics to Participate in Three September Investor Conferences
Silence Therapeutics to Participate in Three September Investor Conferences
SLN

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
SLN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Interim CEO & Chairman of the Board | 1954 |
| Ms. Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director | 1971 |
| Dr. Steven J. Romano M.D. | Executive VP and Chief Research & Development Officer | 1959 |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer | — |
| Ms. Gem Gokmen Hopkins | Head of IR & Corporate Communications | — |
| Mr. Jaimin B. Shah | SVP & General Counsel | — |
| Mr. J.P. Gabriel | Chief Technical Operations Officer | — |
| Mr. Curtis Rambaran M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 77.98
- MACD 12/26/9
- 1.80
- EMA 9 of MACD
- 1.95
- MACD histogram
- -0.15
- SMA 50
- $14.46
- Price above SMA 50
- EMA 50
- $15.54
- Price above EMA 50
- SMA 200
- $9.63
- Price above SMA 200
- EMA 200
- $10.45
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $20.00
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +19.9 | -0.1 | +26.7 | -25.8 | +84.4 | +0.1 |



